Global Cellular Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Cellular Immunotherapy Market is presumed to reach the market size of nearly USD 67.34 BN by 2030 from USD 9.35 BN in 2022 with a CAGR of 24.53% under the study period 2023 - 2030.

Cellular immunotherapy is defined as an innovative cancer treatment approach that uses the cells of our immune system to eliminate cancer. Cellular immunotherapy approaches involve directly isolating immune cells & simply multiplying their numbers, whereas others involve genetically engineered immune cells through gene therapy to enhance their tumor-destroying capabilities. Cellular immunotherapy is widely preferred over old treatment because it provides long-term cancer protection, has lesser side effects, and has been successful in treating different cancers such as breast cancer, prostate cancer, melanoma, lung cancer, and many others. Cellular immunotherapy is performed by directing the immune cells toward cancer-specific targets, activating the immune system to assemble at the target, and triggering an immune response capable of destroying myeloma cells.

MARKET DYNAMICS:

This robust growth of the cellular immunotherapy market is driven by several factors such as increasing acceptance of immunotherapy over conventional therapies, growing emergence of biosimilars, increasing demand for monoclonal antibodies (mAbs), and rising prevalence of cancer among a growing population. The market for cellular immunotherapy will increase due to the increased survival rate of patients who choose it as an alternative treatment option. Other factors propelling the market growth of cellular immunotherapy are an increase in healthcare spending, Increasing R&D activities, easy access to medical insurance, and a surge in technological advancements in cancer treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cellular immunotherapy. The growth and trends of cellular immunotherapy industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the cellular immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy Type

Car T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

By Indication

B-Cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others

By End-Use

Hospitals
Cancer Institutes
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Cellular Immunotherapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cellular immunotherapy market include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc. (Kite Pharma), F. Hoffmann-La Roche Ltd, Merck KGaA, GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Johnson & Johnson, Celyad, Adicet Bio Inc., Dendreon Pharmaceuticals LLC. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11219156

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CELLULAR IMMUNOTHERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy Type
- 3.7.2 Market Attractiveness Analysis By Indication
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY THERAPY TYPE

6.1 Overview by Therapy Type
6.2 Historical and Forecast Data
6.3 Analysis by Therapy Type
6.4 CAR T Cell Therapy Historic and Forecast Sales by Regions
6.5 Dendritic Cell Therapy Historic and Forecast Sales by Regions
6.6 NK Cell Therapy Historic and Forecast Sales by Regions
6.7 TIL Therapy Historic and Forecast Sales by Regions
6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET ANALYSIS BY INDICATION

7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 B-cell Malignancies Historic and Forecast Sales by Regions
7.5 Prostate Cancer Historic and Forecast Sales by Regions
7.6 Liver Cancer Historic and Forecast Sales by Regions
7.7 Renal Cell Carcinoma Historic and Forecast Sales by Regions
7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Cancer Institutes Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL CELLULAR IMMUNOTHERAPY MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CELLULAR IMMUNOTHERAPY COMPANIES

10.1. Cellular Immunotherapy Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF CELLULAR IMMUNOTHERAPY INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Bristol-Myers Squibb Company
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Novartis AG
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Gilead Sciences Inc. (Kite Pharma)
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. F. Hoffmann-La Roche Ltd
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Merck KGaA
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. GlaxoSmithKline plc.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. AstraZeneca
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Pfizer Inc.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Johnson & Johnson
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Celyad
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. Adicet Bio Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Dendreon Pharmaceuticals LLC
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies